ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: TH-PO259

Use of a Wrist-Based Monitoring Device Among Hemodialysis (HD) Patients: A Feasibility Study

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Han, Maggie, Renal Research Institute, New York, New York, United States
  • Preciado, Priscila, Renal Research Institute, New York, New York, United States
  • Thwin, Ohnmar, Renal Research Institute, New York, New York, United States
  • Tao, Xia, Renal Research Institute, New York, New York, United States
  • Tapia, Mirell, Renal Research Institute, New York, New York, United States
  • Rivera Fuentes, Lemuel, Renal Research Institute, New York, New York, United States
  • Mullick, Susmita, Renal Research Institute, New York, New York, United States
  • Grobe, Nadja, Renal Research Institute, New York, New York, United States
  • Thijssen, Stephan, Renal Research Institute, New York, New York, United States
  • Kotanko, Peter, Renal Research Institute, New York, New York, United States
Background

Pervasive sensing technologies allow healthcare providers to gain insights into patients' status outside the clinical setting. To adopt widespread use of remote monitoring devices we must first study their feasibility. We aim to quantify how long patients will use a wearable device before requiring an intervention to maintain use of the device.

Methods

HD patients were enrolled from 3 clinics in New York City starting in May 2019. Patients ≥18 years, on HD ≥3 months, able to walk, owning a smartphone, tablet or PC were enrolled and provided with a wrist-based monitoring device (Fitbit Charge 2). Participants were instructed on how to use the device. If a patient failed to sync data for 7 consecutive days, a text message or email reminder was sent. We evaluated time to first notification using Kaplan Meier analysis. Patients were censored at 5/15/2019.

Results

89 patients were enrolled into our study with 6 patients screen-failed. At enrollment patients were 55±12 years old with a dialysis vintage of 5.8±6.3 years. 36% lived alone, 54% were single, 57% unemployed, 68% were African-American, and 49% had an education level of some college or higher. 61% of the patients required a notification to continue using the device. Mean and median time to first notification were 95 days (95%CI 66 to 125) and 44 days (95%CI 32 to 70 days), respectively. The probability of being on the study without intervention is shown in Figure 1.

Conclusion

We found that most patients will require some counseling to maintain the use of a wrist-based wearable device for remote monitoring. While most patients require an intervention before 90 days into wear, the patients who can maintain use independently after that point are likely to do so for longer.

Funding

  • Commercial Support –